184 related articles for article (PubMed ID: 25482475)
1. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
Wu H; Zhang XM; Zhang HJ; Zhang Q; Chen Z; Huang JD; Lee SS; Zheng BJ
AIDS Res Hum Retroviruses; 2015 Feb; 31(2):260-70. PubMed ID: 25482475
[TBL] [Abstract][Full Text] [Related]
2. Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational Pattern.
Zhang XM; Zhang Q; Wu H; Lau TC; Liu X; Chu H; Zhang K; Zhou J; Chen ZW; Jin DY; Zheng BJ
AIDS Res Hum Retroviruses; 2016 Sep; 32(9):909-17. PubMed ID: 27067022
[TBL] [Abstract][Full Text] [Related]
3. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.
Zhang XM; Wu H; Zhang Q; Lau TC; Chu H; Chen ZW; Jin DY; Zheng BJ
J Antimicrob Chemother; 2015 May; 70(5):1381-90. PubMed ID: 25637519
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
6. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
9. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
[TBL] [Abstract][Full Text] [Related]
10. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
11. Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
Wu H; Zhang HJ; Zhang XM; Xu HF; Wang M; Huang JD; Zheng BJ
PLoS One; 2012; 7(9):e44333. PubMed ID: 22984494
[TBL] [Abstract][Full Text] [Related]
12. Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Guo W; Li H; Zhuang D; Jiao L; Liu S; Li L; Liu Y; Gui T; Jia L; Li J
BMC Infect Dis; 2014 May; 14():237. PubMed ID: 24885612
[TBL] [Abstract][Full Text] [Related]
13. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
[TBL] [Abstract][Full Text] [Related]
14. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
[TBL] [Abstract][Full Text] [Related]
15. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.
Huang Y; Li Z; Xing H; Jiao Y; Ouyang Y; Liao L; Jiang S; Armstrong R; Shao Y; Ma L
PLoS One; 2014; 9(4):e93804. PubMed ID: 24743727
[TBL] [Abstract][Full Text] [Related]
16. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
17. Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
Oumar AA; Jnaoui K; Kabamba-Mukadi B; Yombi JC; Vandercam B; Goubau P; Ruelle J
Acta Clin Belg; 2010; 65(4):242-4. PubMed ID: 20954462
[TBL] [Abstract][Full Text] [Related]
18. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
19. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
20. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]